Drug intelligence / Profile preview

WG105

Development stage: Preclinical
Lead developer: Shenzhen Wingor Biotechnology
Modality: Stem Cell Therapies → Cell Therapies

Overview

WG105 is a preclinical-stage stem cell therapy being developed by Shenzhen Wingor Biotechnology. It is part of a pipeline of cellular drugs aimed at treating a variety of conditions, including neoplasms (cancers) and immune system diseases. As a stem cell-based product, it likely leverages the regenerative or immunomodulatory properties of stem cells, though the specific cell type and exact mechanism of action have not been publicly disclosed. The drug is currently in the early stages of research and development within the company's broader portfolio of stem cell, exosome, and immune cell technologies.

Beyond the preview

Go deeper on WG105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WG105.

Explore the full profile